Do the current guidelines for asthma pharmacotherapy encourage over-treatment?
- 23 July 2020
- journal article
- editorial
- Published by Taylor & Francis Ltd in Expert Opinion on Pharmacotherapy
- Vol. 21 (11), 1283-1286
- https://doi.org/10.1080/14656566.2020.1759551
Abstract
(2020). Do the current guidelines for asthma pharmacotherapy encourage over-treatment?. Expert Opinion on Pharmacotherapy. Ahead of Print.This publication has 15 references indexed in Scilit:
- Is it time to move away from short-acting beta-agonists in asthma management?European Respiratory Journal, 2019
- Strategies to reduce corticosteroid-related adverse events in asthmaCurrent Opinion in Allergy and Clinical Immunology, 2019
- Microarray Immunodiagnostics for AeroallergensCurrent Allergy and Asthma Reports, 2019
- As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild AsthmaThe New England Journal of Medicine, 2018
- Inhaled Combined Budesonide–Formoterol as Needed in Mild AsthmaThe New England Journal of Medicine, 2018
- Influence of inhaled corticosteroids on pubertal growth and final height in asthmatic childrenPediatric Allergy and Immunology, 2016
- Impact of Inhaled Corticosteroids on Growth in Children with Asthma: Systematic Review and Meta-AnalysisPLOS ONE, 2015
- Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendationsAllergy, 2007
- Systemic side effects of inhaled corticosteroids in patients with asthmaRespiratory Medicine, 2006
- A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists.American Journal of Respiratory and Critical Care Medicine, 1994